Valerio Therapeutics (C4X) AI Stock Analysis

0 Followers

Valerio Therapeutics

(Frankfurt:C4X)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue RecoveryThe sharp 2025 revenue rebound indicates improving activity across Valerio Therapeutics’ development programs after a stagnant prior year. If maintained, stronger revenue can support research investment, improve operating leverage, and provide a more durable base for future partnering or financing opportunities.

Negative Factors

Persistent Net LossesValerio Therapeutics remains loss-making despite the 2025 revenue improvement, showing that current activities have not yet produced consistent earnings power. Continued net losses can consume capital, limit financial resilience, and require additional funding before oncology programs generate substantial partnering or commercial returns.

Valerio Therapeutics (C4X) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 278.71M
Dividend Yield: ―
Average Volume (3M): 12.14K
Price to Earnings (P/E): -10.4
Beta (1Y): 0.61
Revenue Growth: 203.22%
EPS Growth: 62.89%
Country: Germany
Employees: 41
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Valerio Therapeutics Business Overview & Revenue Model

Company Description

Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on ta...

Valerio Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:C4X against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:SIGHT	46Neutral	EUR 18.44M	-1.02	52.39%	―	-610.31%	43.88%
FR:TNG	45Neutral	EUR 210.10M	-4.36	-29.36%	―	189.81%	38.50%
FR:ALCLS	44Neutral	EUR 75.87M	-2.29	-94.14%	―	-5.98%	-8.67%
FR:IPH	43Neutral	EUR 147.44M	-2.72	152.56%	―	-29.48%	7.91%
FR:OSE	37Underperform	EUR 40.04M	-1.03	-96.73%	―	-96.25%	-197.89%

* Healthcare Sector Average

Performance Comparison

DE:C4X and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:C4X	Valerio Therapeutics	0.47	0.37	343.93%
FR:IPH	Innate Pharma S.A.	1.39	-0.22	-13.70%
FR:TNG	Transgene SA	0.73	-0.58	-44.43%
FR:OSE	OSE Immunotherapeutics	1.74	-3.90	-69.22%
FR:SIGHT	GenSight Biologics	0.07	-0.04	-35.09%
FR:ALCLS	Cellectis SA	1.35	-1.86	-57.91%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Valerio Therapeutics AI Stock Analysis